Psychological Outcomes in Adolescent and Young Adult Cancer Survivors
Journal of Clinical Oncology · 20.02.2024 · 42 (6) · 707-716
DOI: 10.1200/jco.23.01465 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2024. Verfasst von Meghan E McGrady und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Hauptthemen laut MEDLINE: Cancer Survivors, Neoplasms, Cognitive Dysfunction, Breast Neoplasms. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The diagnosis of cancer during adolescent and young adulthood (AYA) may alter the development and psychological trajectory of survivors across their lifespan. The current review focuses broadly on emotional health, social functioning, health behaviors, and cancer-related cognitive impairment (CRCI) among AYA survivors. Overall, AYA survivors appear to be at elevated risk of emotional distress symptoms, mood and anxiety disorders, suicide, and mental health care service utilization compared with individuals without a cancer history. Difficulties with social relationships and reduced achievement of expected social outcomes including educational attainment and employment have been reported. Despite risk for health-related morbidities, including subsequent neoplasms, many AYA survivors do not engage in health behaviors at the recommended levels for physical activity, diet, or tobacco and alcohol use. Although CRCI has not been comprehensively characterized in this population, subgroups of AYA survivors appear to be at risk for experiencing CRCI, including survivors of central nervous system tumors, Hodgkin lymphoma, testicular, and breast cancer. Across each considered domain of psychological functioning, intervention efforts have largely focused on acceptability and feasibility with an increasing focus on e/mHealth approaches. Future research should include multiphase studies, including randomized controlled trials designed to evaluate intervention efficacy and effectiveness. It is imperative that psychological interventions consider the unique needs of AYA survivors by developmental stage and across multiple levels of influence (patient, support system, institution, and health care system).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- Patient and Family Wellness Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
- Department of Psychology and Biobehavioral Sciences, St Jude Children's Research Hospital, Memphis, TN.
- Department of Surgery, University of Rochester Medical Center, James P. Wilmot Cancer Institute, Rochester, NY.
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.
ORCID-Profile: Meghan E McGrady, Victoria W Willard, AnnaLynn M Williams, Tara M Brinkman
Förderung
- NCI NIH HHS
Zitieren
APA
McGrady, M. E., Willard, V. W., Williams, A. M., & Brinkman, T. M. (2024). Psychological Outcomes in Adolescent and Young Adult Cancer Survivors. Journal of Clinical Oncology, 42(6), 707-716. https://doi.org/10.1200/jco.23.01465
Vancouver
McGrady ME, Willard VW, Williams AM, Brinkman TM. Psychological Outcomes in Adolescent and Young Adult Cancer Survivors. Journal of Clinical Oncology. 2024;42(6):707-716. doi:10.1200/jco.23.01465
BibTeX
@article{McGrady2024,
author = {McGrady, Meghan E and Willard, Victoria W and Williams, AnnaLynn M and Brinkman, Tara M},
title = {Psychological Outcomes in Adolescent and Young Adult Cancer Survivors},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {6},
pages = {707--716},
doi = {10.1200/jco.23.01465}
}
EUVIMED